Market capitalization | $55.73m |
Enterprise Value | $-18.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.34 |
EV/Sales (TTM) EV/Sales | -125.68 |
P/S ratio (TTM) P/S ratio | 371.52 |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue growth (TTM) Revenue growth | 36.36% |
Revenue (TTM) Revenue | $150.00k |
As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.
8 Analysts have issued a InflaRx N.V. forecast:
8 Analysts have issued a InflaRx N.V. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 0.15 0.15 |
36%
36%
|
|
Gross Profit | -0.18 -0.18 |
76%
76%
|
|
EBITDA | -61 -61 |
15%
15%
|
EBIT (Operating Income) EBIT | -61 -61 |
14%
14%
|
Net Profit | -51 -51 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Head office | Netherlands |
CEO | Niels Riedemann |
Employees | 74 |
Founded | 2007 |
Website | www.inflarx.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.